搜索
Nkarta Inc
NKTX添加自选
3.220USD
+0.370+12.98%
收盘 07/02, 13:00（美东）报价延迟15分钟
230.38M总市值
亏损市盈率 TTM
关键数据
2.870今开
3.275最高
1.50M成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
2.10%换手率
2.850昨收
2.820最低
3.27M成交额
亏损市盈率静
0.81市净率
0.00%股息率 TTM
-23.72%ROA
3.65052周最高
2.79量比
-108.79M净利润
71.55M总股本
-1.3488每股收益TTM
0.92Beta
-30.07%ROE
1.63052周最低
15.96%振幅
--毛利率
230.38M总市值
0.64回报/风险
4.49%风险率
TradingKey Nkarta Inc股票评分
单位: USD 更新时间: 2026-07-02操作建议
Nkarta Inc当前公司基本面数据相对谨慎，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名89/387位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价11.80。中期看，股价处于上升通道。近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Nkarta Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Nkarta Inc亮点
亮点风险
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
估值低估
公司最新PE估值-2.39，处于3年历史低位
机构减仓
最新机构持股58.52M股，环比减少30.55%
分析师目标
根据
6
位分析师
买入
评级
11.800
目标均价
+314.04%
涨幅空间
Nkarta Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Nkarta Inc简介
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
公司代码NKTX
公司Nkarta Inc
CEOHastings (Paul J)
网址https://www.nkartatx.com/
相关品种
热门品种
常见问题
Nkarta Inc(NKTX)的当前股价是多少？
Nkarta Inc(NKTX)的当前股价是 3.22。
Nkarta Inc的股票代码是什么？
Nkarta Inc的股票代码是NKTX。
Nkarta Inc股票的52周最高点是多少？
Nkarta Inc股票的52周最高点是3.65。
Nkarta Inc股票的52周最低点是多少？
Nkarta Inc股票的52周最低点是1.63。
Nkarta Inc的市值是多少？
Nkarta Inc的市值是228.70M。
现在Nkarta Inc(NKTX)的股票是买入、持有还是卖出？
根据分析师评级，Nkarta Inc(NKTX)的总体评级为买入，目标价格为11.80。
Nkarta Inc(NKTX)股票的每股收益（EPS TTM）是多少
Nkarta Inc(NKTX)股票的每股收益（EPS TTM）是-1.41。